BFM
QTTB icon

Boothbay Fund Management’s Q32 Bio QTTB Stock Holding History

Boothbay Fund Management’s Portfolio QTTB Stock Details QTTB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-29,575
Closed -$531K – 1988
2024
Q2 		$531K Buy
+29,575
New +$708K 0.01% 973

Other funds holding QTTB

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Boothbay Fund Management's QTTB Position: Q3 2024 in Review

Boothbay Fund Management sold out of Q32 Bio (QTTB) in Q3 2024, closing a stake of 29,575 shares — an estimated $531K sold.

Boothbay Fund Management first reported a position in QTTB in Q2 2024 and held it in 1 quarter. The position peaked at $531K in Q2 2024. 73 funds tracked by Wall St. Rank hold QTTB as of Q3 2024.

  • Boothbay Fund Management reported no remaining Q32 Bio position as of Q3 2024 after selling out during the quarter.
  • Boothbay Fund Management sold 29,575 Q32 Bio shares in Q3 2024, an estimated $531K.
  • Boothbay Fund Management first reported a position in Q32 Bio in Q2 2024 and held it in 1 quarter.
  • Boothbay Fund Management's Q32 Bio position peaked at $531K in Q2 2024.
  • 73 funds tracked by Wall St. Rank held Q32 Bio as of Q3 2024.

Based on Boothbay Fund Management's 13F filing for Q3 2024, filed 14 Nov 2024.